Click a topic below for an index of articles:

 

New Material

Home

Donate

Alternative Treatments

Financial or Socio-Economic Issues

Forum

Health Insurance

Hepatitis

HIV/AIDS

Institutional Issues

International Reports

Legal Concerns

Math Models or Methods to Predict Trends

Medical Issues

Our Sponsors

Occupational Concerns

Our Board

Projects

Religion and infectious diseases

State Governments

Stigma or Discrimination Issues

If you would like to submit an article to this website, email us at info@heart-intl.net for a review of this paper
info@heart-intl.net

 

any words all words
Results per page:

“The only thing necessary for these diseases to the triumph is for good people and governments to do nothing.”


Health & Fitness | March 11, 2003, Tuesday
H.I.V. Lessons Used in Hepatitis C Treatment

By ANDREW POLLACK (NYT) 1380 words
Late Edition - Final , Section F , Page 6 , Column 3

http://query.nytimes.com/gst/abstract.html?res=F50A17FE3C5A0C728DDDAA0894DB404482

ABSTRACT - Drug companies are beginning to test drugs that interfere with enzymes that hepatitis C virus needs to replicate, like protease and polymerase; are encouraged by report from Boehringer Ingelheim, German drug company, that its experimental protease inhibitor reduced viral levels by range of hundredfold to more than a thousandsfold in small number of patients who took drug for only two days; photo (M) Drugs that interfere with H.I.V. have had a major effect in reducing death and disability from AIDS. Now drug companies are beginning to test the first similar drugs for the hepatitis C virus, which can cause fatal liver disease and has infected far more people than H.I.V.


''If they work, they could have the same impact on H.C.V. that the H.I.V. drugs do,'' said Dr. Frank Chisari, a professor of virology at the Scripps Research Institute in San Diego.